Sands Capital Ventures’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Sands Capital Ventures’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-58,895	Closed	-$10.7M	–	22
2023 Q1	$10.7M	Hold	58,895	–	–	2.64%	11
2022 Q4	$11.6M	Hold	58,895	–	–	3.17%	11
2022 Q3	$13.2M	Sell	58,895 -114,000	-66%	-$23.1M	3.85%	9
2022 Q2	$21.9M	Sell	172,895 -95,000	-35%	-$10.9M	6.01%	7
2022 Q1	$34M	Hold	267,895	–	–	7.1%	7
2021 Q4	$35.1M	Hold	267,895	–	–	5.2%	7
2021 Q3	$32.8M	Buy	+267,895	New	+$30.9M	4.94%	6

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Ventures's KRTX Position: Q2 2023 in Review

Sands Capital Ventures sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 58,895 shares — an estimated $10.7M sold.

Sands Capital Ventures first reported a position in KRTX in Q3 2021 and held it in 7 quarters. The position peaked at $35.1M in Q4 2021. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

Sands Capital Ventures reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Sands Capital Ventures sold 58,895 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $10.7M.
Sands Capital Ventures first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Sands Capital Ventures's Karuna Therapeutics, Inc. Common Stock position peaked at $35.1M in Q4 2021.
289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Sands Capital Ventures's 13F filing for Q2 2023, filed 15 Aug 2023.